Guangdong Provincial People's Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1946-01-01

Employees: -

Market Cap: -

Website: http://www.gdghospital.org.cn

Clinical Trials

Effects of Repetitive Transcranial Magnetic Stimulation on Fear of Cancer Recurrence: mPFC-amygdala-hippocampus

Not Applicable

Not yet recruiting

Conditions: Psychology

Interventions: Device: sham low-frequency repetitive transcranial magnetic stimulation
Device: low-frequency repetitive transcranial magnetic stimulation

First Posted Date: 2023-05-31

Last Posted Date: 2023-05-31

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 50

Registration Number: NCT05881889

Correlation of Timing of Pegfilgrastim Administration and PIBP.

Not Applicable

Recruiting

Conditions: Pegfilgrastim
Bone Pain
Quality of Life
Chemotherapy
Breast Cancer
Patient-reported Outcomes

Interventions: Other: Timing of pegfilgrastim administration

First Posted Date: 2023-05-03

Last Posted Date: 2024-05-10

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 156

Registration Number: NCT05841186

Locations: 🇨🇳
Department of Breast Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangzhou, Guangdong, China

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Phase 2

Recruiting

Conditions: RET Driver Mutation
Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation
Non-Small Cell Lung Cancer
BRAF V600 Mutation
MET Amplification
MET Exon 14 Skipping Mutation

Interventions: Biological: Toripalimab
Drug: Nab paclitaxel
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2023-04-05

Last Posted Date: 2023-04-05

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 30

Registration Number: NCT05800340

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guanzhou, Guangdong, China

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Stage III NSCLC
Surgery

Interventions: Drug: Lorlatinib

First Posted Date: 2023-02-23

Last Posted Date: 2023-05-23

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 48

Registration Number: NCT05740943

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery

Recruiting

Conditions: Oligometastatic Disease
Non-small Cell Lung Cancer

Interventions: Genetic: ctDNA testing and whole exome sequencing

First Posted Date: 2022-12-13

Last Posted Date: 2022-12-13

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 60

Registration Number: NCT05648370

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

Completed

Conditions: Chemotherapy
Tumour, Residual
Non Small Cell Lung Cancer
Immunotherapy

Interventions: Drug: Timing of drug administration

First Posted Date: 2022-12-05

Last Posted Date: 2022-12-05

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 110

Registration Number: NCT05637580

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

International Big Data Centre in Emergency Medicine

Recruiting

Conditions: Emergency Medicine

First Posted Date: 2022-11-15

Last Posted Date: 2023-02-23

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 500000

Registration Number: NCT05616416

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting

Completed

Conditions: Esophagus Cancer

First Posted Date: 2022-11-14

Last Posted Date: 2022-11-29

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 350

Registration Number: NCT05615129

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer

Recruiting

Conditions: Esophageal Cancer

First Posted Date: 2022-11-14

Last Posted Date: 2022-11-29

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 100

Registration Number: NCT05615103

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients

Phase 2

Recruiting

Conditions: Patient-reported Outcomes
Immunotherapy
Esophageal Squamous Cell Carcinoma

Interventions: Drug: Paclitaxel-albumin
Drug: Cisplatin
Drug: Carboplatin
Drug: Tislelizumab
Radiation: VMAT or IMRT
Procedure: Esophagectomy

First Posted Date: 2022-10-27

Last Posted Date: 2022-11-28

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 50

Registration Number: NCT05596890

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy